Fas receptor-mediated apoptosis: A clinical application?

Journal of Pathology

Volumn 196, Issue 2, 2002, Pages 125-134

  Timmer, Tineke ^a   De Vries, Elisabeth G E ^a   De Jong, Steven ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anticancer therapy; Apoptosis; Death receptor; Fas; FasL

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CASPASE; CYTOTOXIC AGENT; FAS ANTIBODY; FAS ANTIGEN; FAS LIGAND; GREEN FLUORESCENT PROTEIN; MEMBRANE PROTEIN; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; EXPRESSION VECTOR; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; IN VIVO STUDY; LIVER INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RAT; REVIEW; SOLID TUMOR; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

ANIMALS; ANTIBODIES; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; ENZYME ACTIVATION; FAS LIGAND PROTEIN; GENE TRANSFER TECHNIQUES; HUMANS; MEMBRANE GLYCOPROTEINS; MUTATION; NEOPLASMS, EXPERIMENTAL; NEUTROPHIL ACTIVATION;

EID: 0036153928     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1028     Document Type: Review

References (148)

1. Mechanisms and genes of cellular suicide
2. Monoclonal antibody-mediated tumor regression by induction of apoptosis
3. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins
4. APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia
5. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia
6. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
7. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen
8. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
9. Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein
10. Tumor necrosis factor receptor genes, TNFR1 and TNFR2, on human chromosomes 12 and 1
11. Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13
12. TRAIL: A molecule with multiple receptors and control mechanisms
13. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB
14. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL
15. The human APO-1 (APT) antigen maps to 10q23, a region that is syntenic with mouse chromosome 19
16. The Fas death factor
17. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
18. Molecular cloning of the complementary DNA for human tumor necrosis factor
19. Identification and characterization of a new member of the TNF family that induces apoptosis
20. Transcription stimulation of the Fas-encoding gene by nuclear factor for interleukin-6 expression upon influenza virus infection
21. Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand
22. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes
23. Fas ligand in human serum
24. Fas-mediated cytotoxicity by freshly isolated natural killer cells
25. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity
26. A role for CD95 ligand in preventing graft rejection
27. Fas ligand-induced apoptosis as a mechanism of immune privilege
28. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus
29. Tumor necrosis factor ligand super-family: Involvement in the pathology of malignant lymphomas
30. Apoptosis by death factor
31. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain
32. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor
33. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death
34. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex
35. Caspases: Killer proteases
36. Caspases: The executioners of apoptosis
37. Caspases: Intracellular signaling by proteolysis
38. Lethal effect of the anti-Fas antibody in mice
39. Two CD95 (APO-1/Fas) signaling pathways
40. BID: A novel BH3 domain-only death agonist
41. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis
42. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors
43. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
44. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3
45. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines
46. Fas (APO-1/CD95) signaling pathway is intact in radioresistant human glioma cells
47. Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing
48. Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells
49. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells
50. p53-mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells
51. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells
52. Fas-mediated apoptosis in human prostatic carcinoma cell lines occurs via activation of caspase-8 and caspase-7
53. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells
54. Fas ligand expression in primary colon adenocarcinomas: Evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer
55. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?
56. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape
57. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance
58. Human lung carcinomas express Fas ligand
59. Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines
60. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells
61. Expression of Fas (APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma
62. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
63. Antitumor effect of locally produced CD95 ligand
64. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells
65. Regulation of the proinflammatory effects of Fas ligand (CD95L)
66. Gene transfer of Fas ligand induces tumor regression in vivo
67. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type 1a
68. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder
69. Death pathway genes Fas (Apo-1/CD95) and Bik (Nbk) show no mutations in colorectal carcinomas
70. Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar
71. Somatic mutations in the death domain of the Fas (Apo-1/CD95) gene in gastric cancer
72. Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXII in human glioblastoma multiforme
73. In vivo expression of soluble Fas and FAP-1: Possible mechanisms of Fas resistance in human hepatoblastomas
74. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma
75. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer
76. Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas
77. Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia
78. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia
79. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia
80. Mutations in the Fas antigen in patients with multiple myeloma
81. Somatic Fas mutations in non-Hodgkin's lymphoma: Association with extranodal disease and autoimmunity
82. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells
83. Frequent mutations of Fas gene in thyroid lymphoma
84. Fas splicing variants and their effect on apoptosis
85. Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias
86. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy
87. Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis
88. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
89. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster
90. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis
91. FAP-1: A protein tyrosine phosphatase that associates with Fas
92. Bcl-xL acts downstream of caspase-8 activation by the CD95 death-inducing signaling complex
93. Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis
94. Inhibition of death receptor signals by cellular FLIP
95. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis
96. Casper is a FADD- and caspase-related inducer of apoptosis
97. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis
98. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells
99. CASH, a novel caspase homologue with death effector domains
100. Apoptosis. Placing death under control
101. IAP family proteins - Suppressors of apoptosis
102. X-linked IAP is a direct inhibitor of cell-death proteases
103. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases
104. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases
105. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs
106. The proto-oncogene Bcl-2 and its role in regulating apoptosis
107. Apoptosis in the pathogenesis and treatment of disease
108. Bcl-2 and the regulation of programmed cell death
109. Molecular thanatopsis: A discourse on the BCL2 family and cell death
110. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis
111. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria
112. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
113. Controlling cell death
114. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis
115. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis
116. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
117. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
118. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53
119. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system
120. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells
121. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia
122. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: Requirement of STAT1 protein for up-regulation of Fas and FasL expression
123. Fas expression and function in normal and malignant breast cell lines
124. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation
125. Vitamin E succinate (VES) induces Fas sensitivity in human breast cancer cells: Role for Mr 43,000 Fas in VES-triggered apoptosis
126. NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: The role of reactive oxygen species
127. Fas/APO-1 gene transfer for human malignant glioma
128. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells
129. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs
130. Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells
131. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis
132. Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis
133. Wild-type function of the p53 tumor suppressor protein is not required for apoptosis of mouse hepatoma cells
134. Drug-induced modulation of Fas-mediated apoptosis in human ovarian carcinoma cell lines
135. Acute toxicity of an anti-Fas antibody in mice
136. A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo
137. Inhibition of solid tumor growth by Fas ligand-expressing myoblasts
138. Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL)
139. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo
140. + tumor cells
141. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand
142. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity
143. Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy
144. Intracellular fas ligand expression causes fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis
145. Intravenous injection of cycloheximide induces apoptosis and up-regulates p53 and Fas receptor expression in the rat liver in vivo
146. Potentiation of Fas-mediated apoptosis of murine granulosa cells by interferon-gamma, tumor necrosis factor-alpha, and cycloheximide
147. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression
148. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand